Related Experiment Videos
Tumor suppressor activity of the TGF-beta pathway in human cancers
1Ireland Cancer Center, University Hospitals of Cleveland, OH 44122, USA.
Abstract:
The TGF-betas are a family of cytokines with antiproliferative activity on many cell types. Recent findings demonstrate that the TGF-beta receptor complex functions as a tumor suppressor gene in human malignancy. Somatic mutations of the type II subunit of the TGF-beta receptor (RII) have been demonstrated in several different tumor types. RII frameshift mutations within a short coding region polyadenine repeat are particularly characteristic of colon and gastric cancers that also demonstrate the phenotype of microsatellite instability (RER cancers). These and other mutations as in the type I receptor (RI) are associated with both loss of cell surface TGF beta receptors and with resistance of the cancer cells to TGF-beta-induced growth inhibition. Restoration of receptor expression by gene transfection reverses the transformed phenotype in cancer cells that lacked functional RII or RI. These receptors and, by implication, TGF-beta as well as its complete signalling pathway, are thus new and novel additions to the family of human tumor suppressor genes.
Insights
Transforming growth factor-beta (TGF-β) receptors function as tumor suppressors. Mutations in TGF-β receptors are common in cancers, leading to growth resistance and loss of antiproliferative activity.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Transforming growth factor-beta (TGF-β) are cytokines with antiproliferative effects.
- The TGF-β receptor complex is implicated as a tumor suppressor in human cancers.
- Somatic mutations in TGF-β receptor type II (RII) are observed across various tumor types.
Purpose of the Study:
- To investigate the role of TGF-β receptor mutations in cancer development.
- To understand the functional consequences of RII and RI mutations in cancer cells.
- To explore the therapeutic potential of restoring TGF-β receptor function.
Main Methods:
- Analysis of somatic mutations in TGF-β receptor subunits (RII and RI).
- Characterization of microsatellite instability (RER cancers), particularly in colon and gastric cancers.
- Gene transfection studies to restore receptor expression and assess phenotypic changes.
Main Results:
- Frameshift mutations in RII polyadenine repeats are characteristic of RER+ colon and gastric cancers.
- Mutations lead to loss of cell surface TGF-β receptors and resistance to TGF-β-induced growth inhibition.
- Restoration of RII or RI expression via gene transfection reverses the transformed cancer cell phenotype.
Conclusions:
- TGF-β receptors (RII and RI) function as novel human tumor suppressor genes.
- The TGF-β signaling pathway is critical for controlling cell proliferation and preventing malignancy.
- Targeting the TGF-β pathway offers a potential therapeutic strategy for cancer treatment.